utterbull: The answer to your question "why not wait until they are successful?" is easy---things are going to happen extremely quick here. You sleep, you lose. Don't believe me? Consider:
The company applied for it's CPT (insurance code) at the end of last year, with an expected wait of 12 -18 months. That's right around the corner.
The AIPS will happen sooner than most people realize, because it will be offered through labs as ASR's, generally exempt from FDA approval. It can be sold immediately upon development.
EndoScan, which is due for Phase I approval any moment now, will be offered and sold as an ASR also while waiting for Phase II approval.
The U.S. is in an epidemic, an unprecedented amount of STD's being reported through health services. The world is ready for a more efficent and cost-effective PAP. CCI offers a true razor/razor blade business model, from detection to treatment. Patients and doctors will demand CCI's 80-90% accuracy over the current 30-70%.
80% of all cervical cancers occur in developing nations, where 600 deaths a day are reported. Fertile ground. I have to believe that McCullough is well aware of this need.
P2X7, besides accurately detecting decreased apoptosis in cervical cells, is proving to be effective with other types of epithelial cancers. This wide ranging serving should be a monster source of revenue, and news of any breakthroughs could spike the pps.
According to the 10Q, $48,000 was spent last quarter on packaging design. Inventory is ready to move. All speculation about 'if' is over.
CCI puts $5 revs per test. Net margins remain to be seen. The entire Cytocore Solutions System will cost ~$300.
Better take another look at those 50-50 odds you guys are booking. I'm not very good at math, but even I know that 90% accuracy beats 50%. Or 70%.
That answer your question?
